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ABSTRACT
Oncoprotein p53 actively participates in oral carcinogenesis, in its initiation and/or promotion
of the process. The expression of mutant p53 has been shown to be present in many human
solid tumours of squamous origin including oral squamous cell carcinomas. The wild-type
p53 acts as a tumour suppressor recessive gene, the inactivation of which could lead to
malignant transformation. The wild-type p53 protein appears to block the cell cycle at the
GUS boundary of the cell cycle and to produce GI arrest which provides sufficient time for
DNA repair. On the other hand, its mutant variety forms complexes with the wild-type,
inactivates the wild-type, and thus prevents the wild-type from carrying out its normal
function. This may, in turn, lead to abnormalities in the cell cycle repair system
andeventually to malignant transformation. Mutations in p53 gene may provide the cells with
a growth advantage over the normal cells leading to malignant transformation. This study
investigated the expression of oncoprotein p53 in oral cavity lesions s (60 samples) from
tertiary care hospital Tirunelveli medical college – Tirunelveli, using monoclonal antibodies
with the polymer-HRP (Horseradish peroxidase) indirect immunohistochemical staining
methods. 46/60 Cases were positive for anti-p53 antibody staining and most of the positive
specimens showed diffuse pattern of staining, where the cells were seen as small islands.
Statistical analysis shows that there is a significant correlation between the expression of p53,
cigarette/beedi smoking and the tobacco chewing habits.As the mutant oncoprotein p53
seems to play a role in malignant transformation, more cells are likely to show a strong
nuclear staining reaction when compared to normal or hyperplastic oral epithelia. The
significance of p53 oncoprotein in head and neck tumourigenesis is yet to be understood.
Further studies such as Direct Nucleotide Sequencing, Polymerase Chain Reaction (PCR) and
Single Strand Conformation Polymorphism (SSCP), addressing the possible involvement of
this oncoprotein are warranted to get an insight into the molecular details of the mechanism.
KEY WORDS :
Oral squamous cell carcinoma, p53 oncoprotein, smoking, tobacco chewing.
INTRODUCTION
Cancer is the second most common cause of mortality in the world today. Totally 8
lakh new cases of cancer are reported every year in India of which 48% of cases
among men and 20% among women are tobacco related cancer which is preventable.
Incidence rate of cancers of oral cavity is 7.2 for men and 4.3 for women in India (1).
Smoking tobacco, alcohol consumption, betel quid chewing with or without tobacco
are the implicated as the principal causes for cancers of the oral cavity (2).
Numerous carcinogens are present within the smoke and smokeless form of tobacco
products. These carcinogens combine with the human DNA and forms DNA adducts.
During replication these DNA adducts leads to mutations and derange the cellular
growth control processes (3). p53 gene is one of the important gene involved in
cellular growth and is one of the most common gene mutated in malignant lesions (4).
Various studies have reported p53 gene over expression in premalignant and
malignant lesions of the oral cavity (5). These p53 gene overexpression can be
identified by immunohistochemistry by immunostaining the paraffin embedded tissue
blocks from the lesions of the oral cavity. This study analyses the p53 expression in
lesions of the oral cavity and its relationship with tobacco smoking, chewing betel
quid with or without tobacco.
AIMS AND OBJECTIVESOF THE STUDY
Most of the studies have suggested that there is a six-fold increase in the expression of
p53 oncoprotein in Oral Squamous cell carcinomas (OSCCs). On the contrary, one of
the studies conducted by Ranasinghe et al. (1993) stated that the expression of p53
oncoprotein in oral squamous cell carcinomas is very low (6). The objective of this
study is to determine the extent and pattern of expression of the oncoprotein p53 in
lesions of oral cavity samples from Tirunelveli, Southern India, where the population
is exposed to the same etiologic factors in the same geographical location.
1. To collect data from cases with lesions of oral cavity sent to The Department of
Pathology, Tirunelveli Medical College-Tirunelveli for histopathological
evaluation during the study period.
2. To categorize them into non-malignant, premalignant and malignant lesions.
3. To collect history of tobacco smoking, betel nut chewing in patients with
lesions of the oral cavity.
4. To assess incidence and distribution of malignancy in oral cavity based on age,
sex, site and habitual history.
5. To do p53 immunostaining on these cases and assess the expression of
p53expressionon these lesions.
6. To assess the correlation between p53 expression and history of tobacco
smoking and betel quid chewing.
REVIEW OF LITERATURE
REVIEW OF LITERATURE
ANATOMY AND HISTOLOGY
ORAL CAVITY
The oral cavity refers to the internal part of the mouth and can be divided into the
oralvestibule andthe oral cavity proper. The oral vestibule is the space between the
inner lips, cheeks, and front surface of the teeth. The oral cavity proper is the space
between the upper and lower dental arches, extending from the inner surface of the
teeth to the oropharynx.
Figure – 1.
The structures inside the oral cavity include the  lips,  cheeks,  tongue,  teeth, gingiva,
palates  (hard  and  soft),  salivary  glands, and  tonsils(fig – 1). The structures in the
oral cavity are lined by an oral mucosa, which includes an overlying epithelium and
underlying connective tissue. The oral mucosa can be divided into three types based
on differences in the epithelial covering, organization of the connective tissue, and
associated functions:  lining, masticatory, and specialized mucosa.
LINING MUCOSA is covered by nonkeratinized stratified squamous epithelium with
two distinct layers: the stratum basale and stratum spinosum. The epithelium of the
lining mucosa is similar to the epidermis of the skin, except that it has neither a
stratum corneum nor a stratum lucidum, and the stratum granulosum is often absent.
The nonkeratinized stratified squamous epithelium is moistened by saliva secreted
from salivary glands. The connective tissue adjacent to the lining mucosa can be
divided into the lamina propria and the submucosa. The lamina propria is a thin layer
of loose connective tissue containing many elastic fibres and relatively few collagen
fibres. This layer is equivalent to the dermis of the skin and is located beneath the
epithelium. The submucosa is a thick layer of connective tissue, which contains minor
salivary glands and is attached to the underlying muscle. The lining mucosa covers the
inner oral surfaces of the lips, cheeks, soft palate, the inferior surface of the tongue,
and the floor of the mouth. This type of mucosa is less exposed to abrasion than the
masticatory mucosa. The lining mucosa provides a barrier against the invasion of
pathogens and toxic chemicals, contains receptors for sensations, and serves
immunological functions. The lining mucosa also provides lubrication and buffering
by minor glands in the submucosal layer. Examples of the lining mucosa include the
lip and cheek.
MASTICATORY MUCOSA is covered by keratinized stratified squamous
epithelium, which is exposed to significant abrasion due to high compression and
friction during chewing. The epithelium of the masticatory mucosa is composed of the
stratum basale, stratum spinosum, stratum granulosum, and stratum corneum. It has a
thick lamina propria that contains a dense network of collagen fibres and a few elastic
fibres.  This layer has no submucosa and is directly and firmly attached to the
underlying bone. Masticatory mucosa can be found covering the oral surfaces of the
gingiva and the hard palate. Injection into this area is difficult and painful because of
its sensitive periosteum, high collagen density, and firm attachment to the bone.
SPECIALIZED MUCOSA covers the anterior two thirds of the tongue and consists of
keratinized and nonkeratinized squamous epithelium and numerous papillae. These
papillae can be classified into four types:  filiform, fungiform, circumvallate, and
foliate papillae. Most of these papillae have taste buds. The filiform papillae are the
only papillae without taste buds; their main function is to aid in mixing food during
chewing.
The lamina propria (connective tissue) of the specialized mucosa is attached to the
underlying skeletal muscle. These muscles produce voluntary movement of the tongue
and are innervated by the hypoglossal nerve (cranial nerve [CN] XII). Lining mucosa
covers the inferior surface of the tongue. The mucosa of the tongue is divided into two
parts by a V-shaped groove called the sulcus terminalis. The anterior two thirds of the
tongue is referred to as the body of the tongue. Its mucosa is innervated by the facial
nerve (CN VII) and the trigeminal nerve (CN V). The posterior third of the tongue is
the base of the tongue. Its taste buds and mucosa are innervated by the
glossopharyngeal nerve (CN IX). The posterior third of the tongue contains the lingual
tonsils
1.   Filiform papillae are the smallest and most numerous of the four types of papillae.
They cover almost the entire superior surface of the anterior two thirds of the tongue
and are packed in rows that parallel the sulcus terminalis. Each of the papillae appears
cone shaped with some branching processes. Connective tissue forms the central core
of each papilla. Filiform papillae have no taste buds and extend from the
nonkeratinized stratified squamous epithelium. The surface of the papilla is
keratinized and is exposed to a great deal of abrasion.
2.   Fungiform papillae are less numerous than the filiform papillae. They are
mushroom shaped and are scattered among the filiform papillae. Fungiform papillae
are located at the tip and on the two lateral edges of the tongue. They are more
numerous near the tip of the tongue. Taste buds are found on the apical surfaces of
fungiform papillae.
3.   Circumvallate papillae are large and round with a flat topped cylindrical structure.
There are about 10 to 14 papillae arranged in a row along the sulcus terminalis. Each
papilla is surrounded by a deep groove (moat), which forms a valley around the
papilla. Taste buds are found in the lateral walls of each papilla.
4.   Foliate papillae are leaf like folds with flat tops and have deep clefts between the
papillae. They are located on the   posterior lateral surface of the tongue. They are
more prominent in some animals (such as rabbits) than in humans. Foliate papillae
contain taste buds in the lateral walls of the papillae.
UPPER RESPIRATORY AIRWAY
The upper respiratory airway functions as a part of the conducting portion; it consists
of the nasal cavity, nasopharynx, oropharynx, and larynx. In general, the conducting
airway is composed of bone, cartilage, and fibrous tissue and is lined with stratified
squamous and ciliated pseudostratified columnar epithelia moistened with mucus and
other glandular secretions. Cilia on the surface of the pseudostratified columnar
epithelia sweep particles out of the respiratory airway.
THE NASAL CAVITY is the first portion of the upper respiratory airway. It can be
divided into three regions based on the types of epithelial coverings.
1. The nasal vestibule is the most anterior part of the nasal cavity and is covered
by a keratinized stratified squamous epithelium and vibrissae (stiff hairs); it is
continuous with a mucosa of nonkeratinized stratified squamous epithelium.
2. The nasal mucosa region is covered by pseudostratified ciliated epithelium
(respiratory epithelium), which contains ciliated columnar cells, goblet cells,
basal cells, and, occasionally, neuroendocrine cells. The goblet cells
manufacture mucus, which traps particles of dust and bacteria and moves them
out of the nasal fossa, sinuses, and the nasopharynx, with the help of the ciliary
action of the epithelium. Nasal mucosa filters, warms, and moistens the inhaled
air. Mucus serves as a protective mechanism for preventing pathogens and
irritants from entering the respiratory airway. There is a special vascular
arrangement in the lamina propria of the nasal conchae called  swell bodies
(venous plexuses), which alternately fill with blood from the small arteries
directly into the venous plexuses on each side of the nasal cavity to help reduce
airflow and increase air contact with nasal mucosa.
3. The olfactory mucosa region is located in the roof of the nasal cavity and is
covered by pseudostratified columnar epithelium, which is composed of
ciliated olfactory cells (olfactory receptor neurons), nonciliated columnar cells,
and basal cells. It functions as a site for odorant chemoreception.
THE NASOPHARYNX AND OROPHARYNX conducts air from the nasal cavity
and oral cavity to the larynx. The oropharynx is lined by stratified squamous
epithelium, and the nasopharynx is lined by respiratory (pseudostratified columnar)
epithelium. The nasopharynx contains seromucous glands in the lamina propria. The
pharyngeal tonsil, an unencapsulated patch of lymphoid tissue, is located in the
posterior aspect of the nasopharynx. The palatine tonsils are located at the junction of
the oral cavity and the oral pharynx, between the palatoglossal and the
palatopharyngeal folds, which indicate the posterior boundary of the oral cavity.
Tonsils, rich in lymphoid tissue, are the first line of defense against many airborne
pathogens and irritants.
THE LARYNX conducts air from the pharynx to the trachea. It is supported by a set
of cartilages of complex shape and covered by a ciliated, pseudostratified respiratory
epithelium. This mucosa continues from that of the pharynx and extends to the
trachea. The larynx contains several structures, including the epiglottis, vocal cords,
and nine pieces of cartilage located in its wall. The epiglottis is a thin leaf like plate
structure; its central cord contains a large piece of elastic cartilage. This cartilage is
attached to the root of the tongue and projects obliquely upward behind the tongue and
the hyoid body. The epiglottis stands in front of the laryngeal inlet and bends
posteriorly to cover the inlet of the larynx when food is swallowed. The upper anterior
surface of the epiglottis is covered by nonkeratinized stratified squamous epithelium.
In elderly individuals, the elastic cartilage of the epiglottis is often reduced in size and
is replaced by adipose tissue. The vocal cords (folds), which contain striated skeletal
muscle and ligaments (mainly elastic fibres), are lined by thin nonkeratinized stratified
squamous epithelium, which is firmly attached to the underlying vocal ligaments. The
stratified squamous epithelium protects the vocal cords from mechanical stress. The
main functions of the vocal cords are to control airflow and facilitate speaking (7).
Oral Premalignant and Malignant Lesions
The World Health Organization (1980) has defined a precancerous lesion as
"morphologically altered tissue that is more likely to turn malignant than its
apparently normal counterpart." In the oral cavity, lesions such as leukoplakia,
erythroplakia, and erythro-leukoplakia are considered to be premalignant.
 Leukoplakia is a white, non-scrapable lesion of the oral mucosa, which cannot
be characterized clinically or pathologically as any other disease (8).
 Erythroplakia is a clinical, descriptive term for lesions of the oral mucosa that
constitute bright-red, velvety plaque, and which cannot be characterized
clinically or pathologically as being due to any other condition (9).
High Risk Sites for Oral Premalignant Lesions
WHO (1980) has suggested that the incidence of the premalignant lesions usually
shows a predilection for certain sites: the most common site is the commissures
followed by the buccal mucosa, tongue, vermillion border, floor of the mouth and soft
palate. Alveolar ridge, hard palate and gingiva form rare sites for leukoplakic lesions.
Premalignant lesions associated with smoking usually appear on lips and commissure
whereas the lesions associated with chewing habits tend to be limited to areas like the
buccal mucosa and hard palate. Unlike a Western population, floor of the mouth
leukoplakia is not that common among Asians (10). Erythroplakia and Sublingual
keratosis show the highest degree of risk of turning malignant (50% and >40%
respectively). The degrees of risk associated with oral precancerous lesions are:
Premalignant lesion Risk of malignancy
Leukoplakia 4%-18%
Erythro-leukoplakia 32%
Oral submucous fibrosis 3%-6%
Lichen planus 1% - 10%
Risk of premalignant lesions depends on:
1. Degree of dysplasia, and
2. Location of the lesion.
Dysplasia is the name given to disordered proliferation of tissue which particularly
affects epithelium where there is normally a well-defined pattern of maturation.
Dysplasia is characterized by loss of the normal uniformity of individual cells and a
tendency for disorganization of the tissue as a whole. It can be a prelude to malignant
change (9).
The changes in the epithelium during the development of premalignant lesions can be
classified into different degrees of dysplasia (mild, moderate and severe), a significant
percentage of which bears a certain risk of malignant transformation.
The histologic features of dysplasia are:
(1) Loss of polarity of the basal cells
(2) Basilar hyperplasia
(3) Altered nuclear cytoplasmic ratio (N/C ratio)
(4) Drop-shaped rete pegs
(5) Irregular epithelial stratification
(6) Abnormal mitoses
(7) Mitotic figures in the superficial layers of the epithelium
(8) Cellular pleomorphism
(9) Nuclear hyperchromatism
(10) Enlarged nucleoli
(11) Loss or reduction of intercellular adhesion
(12) Individual cell keratinization in the spinous layer of cells (11).
Dysplasia can be graded as
 Mild when two of the above-listed features are present,
 Moderate when two-to-four features are present
 Severe when more than 5 of the aforesaid features are present.
Carcinoma-in-situ (CIS) lesions show top-to-bottom dysplastic changes in the
epithelium with no signs of invasion into the underlying connective tissue (12). The
likelihood of carcinoma developing from dysplastic lesions has been calculated to be
11%, 33% and 56% for cases of dysplasia in the ascending order of its degree
respectively, suggesting that the risk of - malignant transformation is directly related
to the degree of dysplasia. It is noteworthy that not all dysplastic lesions turn into
squamous cell carcinoma and some of them may even show regressive changes (13).
Squamous Cell Carcinoma
The clinical appearance of small, early squamous cell carcinoma of oral cavity may
vary from a white, thickened, or verrucous lesion to a velvety plaque or a chronic
painless ulcer. More than 90% of SCCs are found to be moderately or well
differentiated tumours and metastasis generally occurs in about 80% of the lesions to
submandibular or cervical lymph nodes (14). Patients with primary oral carcinoma
have a higher risk (4-13%) of developing a second primary, tumour of the upper
aerodigestive tract. The prognosis of OSCCs depends on the nature of metastasis.
Aetiology
A variety of local chronic irritations, acting alone or in combination with each other,
will produce leukoplakic lesions in many susceptible individuals. The factors which
have been suggested to be of etiologic importance in the case of premalignant oral
lesions are tobacco (both smoking and chewing types), alcohol, spices (from diet), and
genetic susceptibility (15). Other factors like papilloma viruses, ionizing radiation,
ultraviolet rays, and such chronic infections such as candidiasis may also play a
synergistic role in the process of carcinogenesis. The lesion commences like a
protective barrier to prevent further injuries to the underlying tissues and carries a
greater risk of malignant transformation, especially in regions such as floor of the
mouth where the lining epithelium is that of the non-keratinized type (16). The
relative risk for oral cancer increases with duration and quantity of a carcinogen
exposure and with the combination of several carcinogens (17).
Genotoxic effects of tobacco smoking and chewing
The most common source of chewing tobacco in several countries in the Asian region
is in the betel quid or pan, which is a preparation of betel leaf (Piper betel), areca nut
(the fruit of areca palm tree), tobacco, lime and catechu (a resinous extract from the
Acacia tree). Sometimes various condiments such as cardamom or cloves are also
added in the quids. This is commonly used in northern parts of India (18). In
Tamilnadu, a southern state of India, the betel quid does not contain any catechu or
spices (Sankaranarayanan et al., 1990). The chewing of betel quid with tobacco has
been established as the principal etiological factor for the high incidence of oral
cancer in India and some other South-East Asian countries (19). Tobacco has also
been implicated as one of the major etiological factors in the development of other
cancers including lung (20) and bladder (21). Potent carcinogenic agents such as
tobacco- and areca-nut-specific nitrosamines have been separated from tobacco and
areca-nut, the major ingredient of the betel quid (22). Many studies have revealed that
the spontaneous generation of reactive oxygen species (ROS) occur during different
stages of carcinogenesis (23). There is an increasing body of experimental evidence
thatingredients of the chewing mixture such as slaked lime play an important role in
the production of reactive oxygen species (ROS) (24). Free radicals such as
superoxide anion, hydroxyl anion and hydrogen peroxide anions are highly reactive
and may bring in changes such as oxidative damage to cellular organelles and DNA,
in turn, leading to genetic damage. This has been experimentally proven by
micronuclei test-the presence of micronuclei in exfoliated cells, especially that of the
oral cavity (25). Many investigators have shown that there is increased occurrence of
micronuclei (26) and/or a higher frequency of sister chromatid exchanges in
peripheral lymphocytes in chronic tobacco smokers and betel quid chewers. Tobacco-
specific nitrosamines (TSNA), known to be potent carcinogens in experimental
animals, may also be causative agents for oral cancers in humans; they may act alone
or in combination with other ingredients such as gum catechu and special flavouring
agents (e.g., pan masala used in northern parts of India) to bring about the genotoxic
effects. Studies have shown that lime together with tobacco and areca nut elevates the
pH (becomes highly alkaline) in the oral cavity in betel quid chewers. Lime may
increase the cell turnover by 'killing' the cells and also the likelihood of heritable
mutations being transmitted to daughter cells before complete DNA repair (27).
Signs and Symptoms
Small tumors of oral cavity are asymptomatic at the time of presentation. Hence high
degree of clinical suspicion is necessary in patients with history of tobacco smoking
and betel quid chewing. Most patients present with advanced disease at the time of
presentation (28).
Symptoms are generally related to the site of involvement. General symptoms include
mucosal growth and ulceration, pain, referred pain to the ear, malodour from the
mouth, difficulty with speaking, opening the mouth, chewing, difficulty and pain with
swallowing, bleeding, weight loss, change of voice, pain neck, blood in sputum and
neck swelling (28).
Site of involvement Symptoms
Buccal mucosa Ulcer with indurated raised margin
Exophytic or verrucous growth
Tongue - anterior 2/3rd Reddish area, nodule, or an ulcer
Floor of mouth Reddish area, ulcer, papillary growth, discomfort, drooling
of saliva
Upper lip Growth, ulcer
Lower lip Usually at the vermillion border as crusty induration or ulcer
Gingiva Ulceroproliferative growth
Alveolar ridge Difficulty in wearing dentures, loosening of teeth, pain and
bleeding
Hard palate Papillary and exophytic growth
Soft palate/uvula Ulcer with raised margin or fungating mass
Tonsils Exophytic growth or ulcer
Base of tongue Ulcerative mass with induration
Submandibular lymph node is involved in more than two thirds of patients of South
Asia with buccal mucosal and gingival cancers. Whereas in patients with cancers of
oropharynx, larynx, tongue, floor of mouth from South Asia more than three fourth
show neck swellings which implicates that most of these patients have neck node
metastasis at the time of presentation.
Diagnostic procedures
Routine radiography for dental involvement
CT imaging is useful for assessing bone involvement
MRI is useful for assessment of soft tissue extension and lymphovascular involvement
Direct pharyngoscopy and indirect laryngoscopy is useful for visualising the lesions of
pharynx and larynx
Biopsies from suspicious lesions are taken avoiding areas of necrosis preferably from
the edge of the lesions. Patients presenting with neck node enlargement a thorough
search for primary lesion is carried out and a biopsy from the primary is preferred.
Fine needle aspiration may be done to assess nodal involvement. When primary could
not be identified then FNAC of the node is done. If it is inconclusive then excisional
biopsy of the lymph node is done as last resort because this procedure compromises
subsequent curative therapy.
Staging
Staging of tumors is done based on the TNM Classification of Malignant Tumours
(29)
Spread of tumor
Lymphatic spread
Oral and oropharyngeal cancers with lymph node metastasis generally have worse
prognosis. Level II group of nodes are the most common group involved followed by
Level I, and Level III. Tumor spread to lymph nodes is predominantly by
embolization rather than permeation.
Hematogenous spread
Multiple levels of neck node involvement and extracapsular spread of tumor are
predictors of hematogenous spread of tumor.  Hemotogenous spread tends to occur via
large veins and lung is the most common site of involvement.
Histopathology
The tumour cells show features of squamous differentiation which includes
keratinization and formation of squamous pearls and features of invasion into the
surrounding structures with disruption of basement membrane and stromal reaction.
They may also show areas of perineural and angiolymphatic spread. Tumours are
graded as follows
Well differentiated resembles closely normal squamous epithelium
Moderately differentiated less keratinization, nuclear pleomorphism, increased
mitoses and abnormal mitotic figures
Poorly differentiated immature cells with minimal keratinization, typical and
atypical mitoses
Most SCCs are moderately differentiated. As such grading has limited prognostic
value. But tumors with infiltrative pattern have poor prognosis and the tumors that
show expansive growth with pushing margins have better prognosis (28).
Immunohistochemistry
SCCs show positivity for cytokeratins. Low grade tumors tend to show positivity for
medium and high molecular weight cytokeratins whereas high grade tumors express
positivity for low molecular weight cytokeratins. (30).
Differential diagnosis
Diagnosing squamous cell carcinoma is not problematic usually. Well differentiated
SCCs should be distinguished from pseudoepitheliomatous hyperplasia. It is
associated with chronic infections like tuberculosis and mycosis, trauma, and granular
cell tumor and lacks cytological features of malignancy. Poorly differentiated SCCs
may be difficult to distinguish from other tumors like melanoma, adenocarcinoma or
neuroendocrine tumor where immunohistochemistry could be used to arrive at the
diagnosis (28).
VARIANTS OF SQUAMOUS CELL CARCINOMA
Verrucous carcinoma is a well differentiated SCC with very low risk of metastasis. It
presents as a slow growing exophytic warty growth. These tumors are characterised
by thickened club shaped papillae with pushing margins of stromal invasion. Well
differentiated squamous epithelium with hyperkeratosis and the cells are larger than
SCC cells but lacks cytological features of malignancy (31).
Basaloid squamous cell carcinoma is an aggressive high grade variant of SCC. It is
characterised by two types of cells basaloid cells and squamous cells. The basaloid
cells are small cells with scant cytoplasm, hyperchromatic nuclei and no nucleoli
which are arranged closely in lobular pattern with areas of comedo type of necrosis
and cystic spaces which are Periodic acid Schiff (PAS) negative and Alcian blue
positive. The basaloid cells and squamous cells are found adjacent to one another (32).
Papillary squamous cell carcinoma presents with an exophytic papillary growth and
has a good prognosis. The cells are arranged in a papillary growth pattern with thin
fibrovascular core covered by basaloid squamous cells with areas of stromal invasion
and adjacent lymphoplasmacytic infiltrates (33).
Spindle cell carcinoma is a biphasic tumor composed of squamous cell and spindle
cell component. The spindle cell component forms the majority of the tumor mass,
which have a mesenchymal appearance but of epithelial origin. The spindle cell
component most commonly resembles fibrosarcoma or malignant fibrous
histiocytoma (34). These cells may also show areas of osteosarcomatous,
chondrosarcomatous or rhabdomyosarcomatous differentiation. Squamous cell
component is usually present in most cases either as invasive carcinoma or in situ
carcinoma. Sometimes where only spindle cell component are seen extensive tissue
sections are needed and immunohistochemistry can be used for differentiation (35).
Acantholytic squamous cell carcinoma is an uncommon variant characterised by
cells arranged in nests with areas of acantholysis of tumor cells creating a
pseudolumina which gives an appearance of glandular differentiation. The
pseudolumina consists of tumor cell debris but negative for mucin production.
Adjacent stroma shows lymphoplasmacytic infiltration (36).
Adenosquamous variant of squamous cell carcinoma is a rare aggressive neoplasm
with both squamous and adenocarcinoma components. The squamous component is
either invasive or in situ carcinoma (37). The adenocarcinoma component is present in
the deeper parts of the tumor where the cells are arranged in tubular pattern with areas
of glands in glands appearance. Mucin is found within the glandular lumen and
intracellular as well.
Lymphoepithelial carcinoma is a poorly differentiated variant of squamous cell
carcinoma with prominent lymphoplasmacytic infiltrates and resembles
nasopharyngeal carcinoma morphologically. The tumor cells are arranged in island
and sheets surrounded by desmoplastic stroma. The cells have moderate eosinophilic
cytoplasm indistinct cell borders with monomorphous vesicular round to oval nuclei
and prominent nucleoli. The tumor is infiltrated by lymphocytes and plasma cells (38).
Immunohistochemically the cells show positivity for epithelial cell markers
cytokeratin and epithelial membrane antigen. It is associated with Epstein Barr
virus(EBV) infection which show positivity for EBV encoded RNA (EBER) (39).
Other tumors that occur in oral cavityinclude squamous papillomas, granular cell
tumor, salivary gland tumors, soft tissue tumors, hematolymphoid tumours,
melanomas and metastatic tumors.
Proto-oncogenes, Oncogenes and Suppressor genes
Several genetic alterations that perturb normal cellular growth and developmental
control mechanisms can lead to abnormal proliferation and differentiation (40). These
include point mutations, deletions, translocations, amplifications and gene
rearrangements, and occur primarily in two classes of genes, namely oncogenes and
tumour suppressor genes. While mutation or amplification of certain genes can lead to
abnormal cellular proliferation, loss or mutation of tumour suppressor genes (which
normally suppress abnormal proliferation), can activate neoplastic transformation
(41). Proto-oncogenes (cellular oncogenes: c-onc) are present in normal cells,
controlling cell proliferation and differentiation. Oncogenes are closely related to
proto-oncogenes, but they have mutated to produce abnormal protein products or to
allow gene over-expression leading to a loss of the normal constraints on their activity
(42). The genes which act by regulating the oncogenes or by producing substances
that antagonize the actions of oncoproteins, are termed tumor suppressor genes
(emerogenes, anti-oncogenes, or recessive cancer susceptibility genes) (43). Mutations
in tumor suppressor gene p53 are considered to be one of the salient features of a large
spectrum of human malignancies. Multiple oncogenes may be involved in oral
carcinoma, especially c-myc with H-ras explained by Field and Spandidos in 1987(44)
or c-erb-B-1 explained by Yarnada et al in 1989 and also by Saranath et al in 1992
(45).
Molecular Lesions in Oral Cancer
A mutation is a change in the nucleotide sequence of the DNA molecule which may
occur within a gene or in the intergenic regions. If a mutation occurs in an intergenic
region it will probably be silent and have no detrimental effect on the cell. But when
the mutation occurs in a gene, it may alter the gene product and generate observable
changes in the organism which is referred to as a change in phenotype. Mutation can
happen at the level of DNA sequences (point mutation, insertion, deletion and
inversion) or at the level of gene. The function of a gene can be blocked at the protein
level by altered gene(s) which encodes a mutant product capable of inhibiting the
wild-type gene product in a cell. Such a mutation would be 'dominant negative'
because its phenotype is manifested in the presence of the wild-type gene, but it
inactivates the wild type activity. Herskowitz (1987) referred to this kind of mutations
as "antimorphs, 'antagonistic mutant genes' having an effect virtually contrary to that
of the gene from which they were derived (46)." Basically, the process involves the
inhibition of function of a wild-type gene product by an overproduced inhibitory
variant of the same product. If a protein has multiple functional sites (e.g., multimeric
nature), a derivative capable of interacting with wild-type polypeptide but otherwise
defective will be inhibitory, especially if it forms multimeric forms which are non-
functional. Hence, dominant negative mutant proteins will retain an intact functional
subset of the domains of the parent wild-type protein, but have the complement of this
subset either missing or altered so as to be non-functional (47). The dominant negative
function is achieved by the formation of inactive complexes (hetero-oligomers)
between the mutant and wild-type p53 proteins (48), and this may, in turn, affect the
sequence specific DNA-binding activity of p53 (49). Mutation in one of the two
alleles of the gene that act in a dominant manner over the normal phenotype (wild-
type) of allele leads to a gain of function, or uncontrolled proliferation. Mutation of
one of the allele followed by loss of, or a reduction to homozygosity in the second
allele will lead to a loss of regulatory effect on cell proliferation (50). p53 oncoprotein
appears to block the progression of cells through the late presynthetic phase of
replication: mutant forms may fail to maintain this control or may even stimulate cell
proliferation (51). The most frequently documented genetic change in human oral
cancer is in the short arm of chromosome 17 (17p), in the region of the suppressor
gene p53. Mutations or deletions in onco-suppressor genes may give rise to defective
suppressor proteins thereby leading to the loss of tumour suppressor function. Such
genetic markers as p53 may play an important role in the development of oral
squamous cell cancers, and give some insight into the molecular mechanisms that are
responsible for neoplastic transformation (52). Mitogenic agents such as epidermal
growth factor produce pleiotropic response involving the activation of various
biochemical processes that are responsible for cellular growth and development. The
interaction of the growth factor and its effects on oral mucosa will be described in
subsequent sections
Mitogen-Activated Protein Kinases (MAP kinases)
The growth signals obtained at the cell surface are transduced to the nucleus through a
cascade of tightly regulated phosphorylation events mediated by kinases such as
protein kinase-C (PKC), casein kinase and mitogen activated kinases (MAPK). Recent
studies have shown that the ligands that bind to epidermal growth receptor may also
act through the receptor-specific threonine kinases (53). There is an increasing body
of evidence which suggests that these kinases play an active role in the cellular
proliferation and/or differentiation (54). Since many membraneassociated growth
factor receptors have been shown to exhibit ligand-dependent proteintyrosine kinase
activity, it is thought that tyrosine phosphorylation is an early event in the propagation
of signal transduction cascade. Furthermore, oncogenes that are improperly regulated
have been shown to induce cellular transformation via aberrant phosphorylation of
tyrosine residues (55). An important kinase among these enzymes, originally named
microtubule-associated protein kinase-2 (MAP-2) because it phosphorylates
microtubule-associated protein, is now referred to as mitogenactivated protein kinases
(MAP kinase) (56). The MAP kinase (MAPK) requires both tyrosine and threonine
phosphorylation for activity and recent studies has revealed that MAP kinase is not a
single enzyme, but a family of kinases that have been to referred to as Extracellular
signal Regulated Kinases (ERKs) (57). Depending upon the in vitro substrates that
have been used to characterize these kinases, they are again subdivided into myelin
basic protein kinases or MBP, ribosomal S6 protein kinase-kinases (RSKs) and EGF-
receptor threonine kinases or ERK (58). The role of MAPK in signal transduction
pathways may be summarized as follows: Signals initiated by receptor tyrosine
kinases (RTKs), by protein kinase-C or by signal transducing G-proteins rapidly
converge and activate the cytoplasmic MAPK via phosphorylation of tyrosine and
threonine. The activated MAPK then activate the RSKs by serine threonine
phosphorylation, which helps the RSKs to phosphorylate their targets such as
ribosomal S6 protein. One of the MAPKs, epidermal growth factor receptor-tyrosine
kinase (ERT kinase) is proposed to down-regulate the activity of EGFR soon after
ligand binding while RSK has the potential to turn off a variety of signal transducers
that are modulated by tyrosine- or serine threonine phosphorylation via other kinases
that may, in turn, activate RSKs (59). Many extracellular stimuli that influence cell
proliferation and differentiation, including growth factors, cytokines and hormones
can stimulate MAP kinases and the activation of MAPKs require phosphorylation of
tyrosine and threonine residues. Studies concerning the mechanism of activation of
MAPKs are in progress now (60).
Tumour Markers
Neoplastic transformation is a multistage process which involves a number of aberrant
genetic events that are progressively associated with the acquisition of a state of
malignancy. Many oral cancers are known to arise from premalignant lesions. The
substances (eg, oncoproteins, enzymes, growth factor receptors), that are used to study
the changes in preneoplastic as well as neoplastic tissues, are referred to as tumour
markers (61). A number of growth factors such as epidermal growth factor
(EGF) and transforming growth factor alpha (TGF-α) and -beta (TGF-β) show altered
expression, or disregulated production during the process of carcinogenesis (62). An
increased production of growth factors may indicate the presence of
abnormal growth or some disturbances in cellular proliferation. Altered proliferation
or differentiation may also be induced by deregulation of tumour suppressor genes
such as p53 (63).
Onco-suppressor gene p53
p53, a proto-oncogene product, is a cellular protein expressed in low levels in non-
transformed cells. On the other hand, tumour-derived cells and transformed cell lines
show a many-fold increase in the expression of p53 (64). Unlike the proteins of non-
transformed cells, the mutant protein is likely to form complexes with transforming
proteins of viruses such as Simian Vacuolating virus (SV40) leading to the acquisition
of a stable conformation than the wild-type protein. The results of several studies have
supported the view that increased levels of p53 effect changes in the phenotype of
normal cell and that over-expression of the protein leads to the immortalization of cell
lines. It is suggested that over-expression of p53 is a common event in the multistep
carcinogenesis in colo-rectal carcinomas and oral squamous cell carcinomas (65).
Functions of p53
Finlay et al. (1988) have demonstrated that the wild-type sequence of the proto-
oncogene does not code for a transforming protein, but loss of function or mutation in
the gene possibly transactivates the protein culminating in malignant transformation.
The p53 protein appears to block the progression of cells through the late G1 phase of
replication: mutant forms fail to perform this function and may even stimulate cell
proliferation (66). A clear relationship has been established between p53 expression
and heavy smoking and alcohol consumption and the protein appears to play a central
role in oral carcinogenesis, possibly being mutated by carcinogens in tobacco and
alcohol (67). Studies using ‘high-tech’ devices have revealed that p53 has a possible
role in the control of mRNA synthesis and/or maturation (68). Analysis of non-
transformed cells, non-SV40-transformed cells, and growth-arrested and –stimulated
mouse cells have revealed that the p53 plays an important role in the cell cycle and the
subcellular distribution of the protein varies throughout the cell cycle. p53 forms high
molecular weight complexes with E6 proteins of the human papilloma virus types 16
and 18 ), heat shock proteins and protein kinases (69). Since p53 is a nuclear protein
which seems to be involved in the regulation of cell cycle, especially DNA replication
and transcription, the mutant variety of the protein shows a relatively high affinity for
binding to single stranded DNA than to double-stranded DNA. Although this is true,
the wild-type protein p53is more efficient in binding SV40 DNA fragment which
consists of the sequences known to regulate the activity of SV40 promoters. Hence, it
is possible that the protein plays a dual role by involving in DNA replication and in
the regulation of gene expression (61).
The p53 tumour suppressor gene is a frequent target for structural alterations in a large
number of human malignancies. The levels of wild-type p53 increase in response to
DNA-damaging agents such as ionizing radiation, leading to G1 arrest. Because of
high levels, p53 may transcriptionally induce the expression of the growth arrest and
DNA damage protein, GADD45, resulting in the inhibition of progression from GI
into S phase (62). Over-expression of wild-type p53 in transformed cells can arrest
cell - proliferation, reverse a tumourigenic type, and sometimes induce apoptosis or
differentiation. The wild-type p53 has been shown to be capable of attaching to
specific DNA sequences thereby acting as a transcriptional modulator. Furthermore,
over-expression of wild-type p53 represses transcription from a variety of promoters
probably through basal transcription factors. Studies have revealed the existence of a
p53-binding protein, which can associate with both wild and mutant types of the
protein (63). Momand et al. (1992) have identified this protein as the product of
murine double minute (MDM2), a putative proto-oncogene, over-expression of which
interferes with sequence-specific transcriptional activation by wild-type p53. Over-
expression of wild-type p53 is capable of sequencespecific binding to a region within
the mdm2 gene and of transactivating directly this gene (64). High levels of Mouse
double minute homolog-2 (MDM2) protein, similar to the DNA tumour virus
oncoproteins may inactivate the tumour suppressor activity of p53 by complexing to it
(65). It is also possible that the increased levels of wild-type p53 may transactivate
EGF receptor promoter sequences and that there exists a common regulatory
mechanism to control cell proliferation mediated through both p53 and EGF receptor
(66).Mutations that activate transformation may be the ones that result in a loss of
function of the wild-type p53. Finlay et al. (1989) suggested that over-expression of
p53 mutants enhances the transformation process by the formation of non-functional
multimeric complexes which can inactivate wild-type of the protein thereby giving a
growth advantage over the other cells. Since the p53 acts as a tumour suppressor gene,
it possibly gets involved in the negative control of growth and differentiation via its
protein product (67). This shows that the interaction of mutant forms of the
oncoprotein with that of the wild-type would switch off the activity of the latter or
considerably decrease its endogenous tumour suppressor activity (dominant negative);
thus, making the cell to be deficient in the function of that gene product. There is also
evidence that at least some mutant p53 proteins may also play a key role in allowing
cells to enter the S-phase which fails to correct DNA damage. In other words,
overexpression of the mutant p53 and its interaction with that of the wild-type protein
makes the cell more susceptible to uncontrolled proliferation (68). It seems that p53
mutation is an important step for cell transformation in vivo.
p53 Expression in other areas
Although the expression of proto-oncogene product p53 is very low in normal non-
transformed cells, most of the neoplastically transformed cell lines show a many-fold
increase in the levels of the oncoprotein. Mutations of p53 gene have been reported in
most of malignant tumours: breast, liver, lung,colo-rectum and bladder (65).
p53 and Oral Cavity Lesions
Heavy smoking and drinking or tobacco smoking coupled with tobacco/betel quid
chewing are the major parameters which correlate with the over-expression of
oncoprotein p53 in patients with Oral cavity squamous cell carcinoma. The high
percentage of p53 positivity, in heavy smokers, may be due to accumulation of
chemical carcinogens in the tissues over time. Field et al. (1991) suggested that the
excess carcinogen may damage the integrity of the gene leading to its over-expression
and that there might be a loss of suppressor activity with a gain in the dominant
transforming activity. It has been established that GT transversions are the most
frequent p53 mutations in non-small cell lung cancer and in oesophageal squamous
cell carcinomas. It is worth noting that benzopyrene, a major carcinogen in tobacco
smoke, is known to induce GT transversions. This strongly suggests that tobacco
use, a known risk factor in oral squamous cell cancer, is linked with the mutations that
occur in the gene on prolonged exposure to tobacco smoke (69). A number of
publications have shown that there is over-expression of p53 oncoprotein in oral
SCCs. The percentage of oral SCCs positive for p53 varies from 35% to 93.5%, with
most of the reports showing a positive reaction in more than 50% of the cases. The
average percentage of p53 staining in oral SCCs is 60.5. However, a recent paper by
Ranasinghe et al. (1993) showed a very low percentage (11%) of oral SCCs that were
positive for p53 from a South Asian population. The sharp contrast of the result from
this study as compared with those of other studies raises the possibility that there
might have been technical problems in the staining procedures. On the other hand, it is
well known that the etiological factors for oral malignancies in the South Asian
population are different from those of the Western World (70). In Western countries,
oral SCC only accounts for 5% of all the cancers and the main etiological factors are
smoking, and alcohol or a combination of the two. In the South Asian population, oral
SCCs accounts for more than 40% of all cancers (71) and the main etiological factors
are betel quid with tobacco chewing and tobacco smoking (72). It is, therefore,
possible that the low percentage of p53 expression in oral SCCs from the South Asian
population by Ranasinghe and his associates (1993) may reflect the differences in the
etiological factors when compared to other parts of the world. It is likely that a large
sample containing more SCC cases might draw more reliable conclusions. Further
studies are needed to give more insight into the functional aspects of p53 in oral
squamous cell carcinomas.
Overview of Immunohistochemistry
Immunohistochemistry is a combination of anatomical, immunological and
biochemical technique. It identifies the specific components of the cells by interaction
of the target antigens with visually labelled antibodies. It helps to visualise the
distribution and localisation individual cell components within the cells. There are
many approaches and methodology in IHC but they are broadly divided into two
groups i.e., sample preparation and labelling.
Introduction - History
Even though the principle of IHC has been known since 1930, only in 1942 Coons et
al reported the first IHC study.  He identified pneumococcal antigens in the infected
tissue by using fluorescein isothiocyanate labelled antibodies. Later on many
improvements and modifications has been made in the field of protein conjugation
label detection, tissue fixation, antigen retrieval and light microscopy. Now IHC has
become a routine tool in diagnostic and research laboratories.
Applications
IHC is used for diagnosing diseases, development and assessment of drugs and in
biological research activities. In pathology IHC is used as a diagnostic tool to identify
benign and malignant tumors, staging and grading of tumors and helps in identifying
the cell of origin in metastatic tumors.
Individual tissue samples are prepared on the slides, processed and stained and
visualised. Tissue microarray techniques allow multiple samples to be prepared  on a
single slide for comparative analysis and is also cost effective and less time
consuming. Automated techniques are available for sample preparation and staining.
The samples are visualised by either light microscopy or fluorescent microscopy.
Recent advances in technology have enabled in high quality image capturing and
image analysis and quantification of multiple IHC parameters.
Sample preparation
Sample preparation is a critical step in IHC as it helps in maintaining the cell
morphology, tissue architecture and preserving the antigenicity of the target epitopes.
Tissue Collection
Fresh tissues are preferred for IHC but it can also be done on formalin fixed tissues.
Biopsies are generally preserved in formalin immediately and sent for IHC analysis.
Tissues admixed with blood are washed with water prior to fixation as hematologic
antigens may interfere in detection of target antigens.
Tissue Fixation
Tissues are fixed chemically either by cross linkage of proteins or by denaturation of
proteins rendering them insoluble. Prolonged fixation or improper fixation can cause
masking of the target antigens so right fixation method has to employed based on the
target antigen to be analysed.
Formaldehyde is the most common fixative used. It is a semi-reversible, covalent
crosslinking reagent that allows tissues to be immersed or perfused for prolonged
period of time depending on requirements.
Tissue Embedding
In order to maintain the natural shape and architecture of samples for long term
storage and thin sectioning the tissue samples are embedded in paraffin wax. Certain
samples that are too sensitive for chemical fixation or which could be removed during
the process of dewaxing are embedded in cryogenic medium and then snap frozen in
liquid nitrogen.
Sectioning and Mounting
The decision to section tissue is dependent on the application to be used. For whole
mount IHC when the samples are of less than 5mm thickness sectioning is not
required. Samples that require multiple staining procedures sectioning is needed.
Formalin fixed tissues that are embedded in formalin are sectioned into thin slices of 4
to 5µm thickness using a microtome. These sections are then mounted on the adhesive
coated or positively charged slides. The commonly used adhesives are 3-
aminopropyltriethoxysilane (APTS) or poly-L-lysine. Other physical adhesives like
gelatin, egg albumin or Elmer’s glue are also used. After mounting the sections the
slides are dried in the oven or microwave before proceeding to deparaffinization.
The frozen section are cut using a pre-cooled cryostat and mounted onto the adhesive
glass slides, followed by overnight drying at room temperature and fixed with pre-
cooled -20°C acetone. Depending on the target antigens this step may be skipped.
Tissue section must be deparaffinised before staining because wax interferes with the
penetration of the reagents. For the labelled antibodies to specifically bind to the
correct epitopes the formalin fixed tissues must be also pre-treated to unmask the
antigens.
Deparaffinizing (Clearing) and Rehydrating
Xylene is miscible with paraffin and alcohol and is most commonly used to remove
paraffin from the tissue sections. The slides left in three changes of xylene for 5 to 10
minutes. After clearing the sections are rehydrated in decreasing grades of alcohol
with water starting with absolute alcohol 10 minutes each. The sections are then taken
to distilled water wash. The number of washes and the reagent concentration are
standardized according to the laboratories and optimized for antigens and tissue
samples accordingly. To avoid non-specific antibody staining and high background
staining the section should never be allowed to dry before mounting.
Antigen Retrieval
Formaldehyde forms methylene bridges between the proteins which in turn interferes
with the epitope recognition of the primary antibodies. These methylene bridges are
removed by two methods.
Heat induced epitope retrieval (HIER)
This is most commonly used method for antigen retrieval. Microwave oven, pressure
cooker or vegetable steamer is used as the heating sources with buffers such as
Sodium citrate or Tris/EDTA.  The temperatures, pH of the buffer and incubation time
are the critical factors involved in this method.
Proteolytic induced epitope retrieval (PIER)
Proteolytic enzymes such as pronase, pepsin, ficin, trypsin or proteinase K are used to
partially digest the proteins and unmask the antibody epitopes. The proteolytic
enzyme concentration and the incubation time are the critical factor involved in this
method. Both methods can either be used separately or I combination. In alcohol fixed
tissue samples antigen retrieval increases the antigenicity of the samples.
Blocking Endogenous Targets for IHC
Immunohistochemistry uses reagents like peroxidases and biotin, which are also found
in tissues and these, may cross react with antibody and interfere with the antigen
detection. This may lead to false positive results. Hence before primary antibody is
added to tissue sections these endogenous factors are blocked so they do not interfere
with antibody epitope detection.
Peroxidases
Horse radish peroxidase is the most commonly used reporter for target antigen
detection which is coupled with 3,3-diaminobenzindine (DAB) chromogen.
Endogenous peroxidases and pseudoperoxidases present normally within the tissues
reacts with hydrogen peroxide to reduce DAB chromogen and resulting in non-
specific staining of tissues.
This is circumvented by using 3% hydrogen peroxide in methanol or water which
supresses the endogenous peroxidase activity if there is any, after adding primary
antibody. Endogenous peroxidase activity in tissue sections can be assessed by
treating the formalin fixed tissues directly with peroxidase substrate such as DAB, and
formation of colored precipitate will indicate the presence of endogenous peroxidase
activity.In tissues that are rich in endogenous peroxidase activity alternatively calf
intestine alkaline phosphatase can be used as enzyme label.
Endogenous peroxidase block is done after adding the primary antibody and before
adding the peroxidase conjugate so that it does not interfere with the immunoreactivity
of the primary antibody.
Blocking nonspecific sites
Antibodies generally bind to specific epitopes. But they may also bind weakly or
partially to sites non-specific proteins also known as reactive sites that are similar to
the cognate binding sites of the target antigen. This leads to non-specific background
staining which in turn interferes with the target antigen detection. Buffers such as
normal serum, non-fat dry milk, Bovine serum albumin (BSA) or gelatin and other
commercial buffers blocks the reactive sites.  Blocked reactive sites do not interfere
with primary or secondary antibody and thus reducing the background staining.
Sample labelling – Immunodetection
Detecting the target antigen with antibodies is a multistep process and it requires
optimization at every level to maximise the signal detection. Both primary and
secondary antibodies are diluted in the buffer. This helps in uniform dissemination of
antibody throughout the sample, stabilisation, and reduces the non-specific
background staining. The diluent used is optimized for the specific antibody used.
In between antibody application the section are rinsed in rinse buffers which remove
the unbound antibodies and weakly bound antibodies to the non-specific reactive sites
and thus reducing the background staining. Rinse buffers are usually simple solution.
Antibody-mediated antigen detection approaches are separated into direct and indirect
methods.
Direct method
The primary antibody is directly coupled with the conjugate which can either be a
flourochrome or an enzyme. The labelled primary antibody reacts with the antigen
directly. The disadvantage of this method is that there is no antigenic signal
amplification.
Indirect method
The antigenic sites on the primary antibody react with the labelled secondary
antibody. Horse radish peroxidase is the most commonly used label together with
chromogen substrate. This method allows for antigenic signal amplification as many
secondary antibodies can react with different antigenic sites of a single primary
antibody and same secondary antibody can be used against different primary
antibodies of same species.
In Polymer chain indirect method the secondary antibody is conjugated with
peroxidase enzyme which is labelled with a polymer such as dextran chain. Dextran
chain polymer has up to 70 enzymes and 10 secondary antibodies. This method is
quick, easily reproducible and reliable. This is the most common method used in
diagnostic laboratories.
The target antigens are detected either by chromogenic method or fluorescent method.
For fluorescent detection the primary or secondary antibody is conjugated with a
flourophore which is then detected by fluorescent microscopy. Chromogenic method
employs enzymes such as horse radish peroxidase or alkaline phosphatase which
produces insoluable colored precipitates on reaction with DAB or nitro-blue
tetrazolium(NBT) and 5-bromo-4-chloro-3'-indolyphosphate(BCIP) that can be
detected by light microscopy.
Chromogenic counterstains
Hematoxylin is most commonly used. Hematoxylin on oxidation combines with
aluminium ions to form an active metal dye complex which on binding with the lysine
residues within the histones of mammalian dna produces dark blue staining of the
nucleus. Nuclear fast red reacts with the nucleic acids resulting in red nucleus. Methyl
green stains the nucleus green.
Fluorescent Counterstains
DAPI (4', 6-diamino-2-phenylindole) and Hoechst are common nuclear dyes used for
fluorescent IHC.
Sealing the Stained Sample
After all staining is completed; the sample should be preserved for long-term usage
and storage and to prevent enzymatic product solubilisation or fluorophorephoto
bleaching. Sealing the sample by mounting a coverslip with an appropriate mountant
stabilizes the tissue sample and stain. An antifade reagent should also be included if
fluorescent detection will be performed to prolong fluorescence excitation. The
coverslip can then be sealed with clear nail polish or a commercial sealant after the
mountant has cured to prevent sample damage.
Sample Visualization
Once the sections are prepared, the samples are viewed by light or fluorescent
microscopy, depending on the antibody detection method.
MATERIALS AND METHODS
MATERIALS AND METHODS
The present study is a retrospective study. Biopsies from ENT and Dental department
Tirunelveli medical college received for routine histopathological evaluation in the
department of Pathology, Tirunelveli medical college during the study period were
taken for this study. This study comprises 60 specimens received during November
2014 till May 2015.
The habitual history is obtained from histopathological requisition form and case
history from case sheet
Methods of study:
 Complete clinical history of the patients presenting with leukoplakia,
erythroplakia, mucosal ulcer, growth, or pain in the upper aero digestive tract.
 Complete personal history of patients with details of smoking history, betel nut
chewing, pan or gutkha taking habit including total duration, frequency per day
and amount of consumption per day.
 Histopathological evaluation of the specimens of hematoxylin and eosin
stained slides.
 p53 immunostaining and evaluation of the specimens.
Sample size:
60 cases of Oral cavity lesions from November 2104 till may 2015
Sample design:
Purposive sampling
Inclusion criteria
 Cases received for histopathological evaluation at Department of Pathology
Tirunelveli Medical College, Tirunelveli.
Exclusion criteria
 Specimens not sent in formalin
 Specimens with inadequate history
Study period
From 2014 to 2015
Place of study
Department Of Pathology
Tirunelveli Medical College
Tirunelveli
Brief procedure:
Demographic profile, relevant clinical history like age, sex, habitual history etc.
were recorded for all patients from the clinical case records.
The received biopsy specimens are subjected to fixation in 10% neutral
buffered formalin .After adequate fixation (usually 24 hours) surgical grossing was
done according to the standard protocol and a detailed gross description was made.
Extensive sampling is done to search for suspicious areas and then tissue sections are
taken and subjected to routine manual tissue processing and paraffin embedding.
Sections of 4-5 µ thickness were taken and routinely stained with haematoxylin and
eosin (H & E) and mounted with DPX mountant .The slides are examined under a
light microscope. Cases are grouped as non-malignant, premalignant and malignant.
Cases of squamous cell carcinoma were graded based on histomorphological analysis
as
 Well differentiated,
 Moderately differentiated
 Poorly differentiated
All these cases are further subjected for immunohistochemical analysis with p53.
IHC Procedure:
APES coated slides
 Amino propyl triethoxy saline (APTS) - 2ml
 Acetone - 98ml
Acid clean slides are kept in acetone for 2 minutes, transferred to 2% APTS for 2
minutes then finally transferred to acetone for 30 seconds. Allow to air dry and keep
the slides in dust free box. These slides are used for taking sections from paraffin
blocks.
 Incubate the slides in incubator for 1 hour at 55°C temperature.
 Deparaffinise the sections in 3 changes of xylene 5 minutes each.
 Hydrate the sections in decreasing grades of alcohol from absolute alcohol, to
90%, and 70% of alcohol. Bring the sections to water.
Antigen retrieval solution
 Citrate bath (pH 6.0)
 Tris sodium citrate 2.96gms
 Distilled water 1000ml
Slides are kept in boiling solution in cooker for 20 minutes at 100°C.
Tris buffered saline (TBS) pH 7.4 to 7.6
 Sodium chloride 20gms
 Tris 1.512 grams
 Distilled water 2500ml
Adjust pH with 1N HCL (Concentrated HCL – 10 ml and Distilled water - 90ml)
Staining procedure
Super sensitive polymer-HRP detection system is used and moisture tray is used for
staining
 Apply peroxide block to the specimen according to tissue size and incubate for
10 minutes at room temperature.
 Wash in TBS twice, each for 5 minutes, drain and blot gently around the
section.
 Apply power block and incubate for 10 minutes at room temperature.
 Without washing apply appropriate primary antibody and incubate for 30
minutes at room temperature (20 degrees to 22 degree Celsius).
 Wash in TBS twice each 5 minutes, drain and blot gently around the section.
 Apply Polymer-HRP reagent and incubate for 30 minutes at room temperature
(20 degrees to 22 degree Celsius).
 Wash in TBS twice each 5 minutes, drain and blot gently around the section.
 Apply working chromogen substrate solution and incubate for 10 minutes at
room temperature (20 degrees to 22 degree Celsius) or until acceptable color
intensity has been reached.
 Wash with TBS buffer followed by distilled water.
 Counter stain in hematoxylin for 15 – 30 seconds.
 Wash with distilled water – 2 changes
 Dry, clear and mount with DPX mountant.
Development of brown color indicates positive staining.
Habitual history:
Tobacco smoking and betel quid chewing history is collected from the
histopathological request and from the clinical data of case sheets. These cases are
further subdivided into
Group 0 – non-smokers with no history of smoking
Group 1 –history of smoking 1 to 5 cigarettes or beedis per day
Group 2 – history of smoking 6 to 10 cigarettes per day
Group 3 – history of smoking more than 10 cigarettes per day
Similarly betel quid chewers are grouped as
Group 0 – no history of chewing tobacco
Group 1 – history of chewing 1 to 5 betel quids per day
Group 2 – history of chewing 6 to 10 betel quids per day
Group 3 – history ofchewing more than 10 betel quids per day
Statistical analysis:
The intensity of p53 oncoprotein staining reaction was graded as follows:
negative or equivocal -
weakly positive +
moderately positive ++
strongly positive +++
The pattern of the staining for p53 positive cells was classified according to the
number of positive cells in a given field; scattered when only a few positive single
cells were seen in a given field, and diffuse when a large number of positive cells
were clumped together in a given area (65). Fischer’s exact test of significance is
performed to examine the association between staining intensity (measured on a 4-
point scale) and degree of malignancy. To analyze the correlation between the
expression of p53 oncoprotein and the chewing habits (frequent chewers Vs
infrequent chewers), the Fisher Exact test of significance was used.
RESULTS
RESULTS
Table - 1. Tobacco Chewing
habits (Betel quid/Pan
masala/Gutkha). Table - 2. Smoking habits.
Tobacco
Chewing Habits
No. of
Cases Smoking Habits No. of Cases
Non Chewers 8 Non-Smoker 25
Chewers 52 Smoker 35
Total 60 Grand Total 60
Chart - 1 Chart - 2
The above charts and tables show that the percentage of non-smokers is high
compared to the percentage of non-chewers of tobacco. It is partly due to the
fact that none of the female cases in the study group had a history of smoking
habit. But betel quid chewing is much more prevalent among females.
13%
87%
Tobacco Chewing
habits
Non Chewers Chewers
42%
58%
Smoking habits
Non-Smoker Smoker
Table - 3. Smoking habits among age groups
Age Distribution Smoking Habits TotalNon-Smokers Smokers
21-40 4 3 7
41-60 10 14 24
>61 11 18 29
Total 25 35 60
Chart -3
The habit of smoking is more in the older age groups than in the
younger adults within the study population
7%
17% 18%
5.0%
23.3%
30.0%
21-40 41-60 >61
Percentage
of Cases
Age distribution
Age distributon of Smoking
Non-Smokers
Smokers
Table - 4. Tobacco Chewing (Betel quid, Pan masala, Gutkha)
habits among the age group
Age groups Tobacco chewing habits Total
Non-Chewers Chewers
21-40 1 6 7
41-60 3 21 24
>61 4 25 29
Total 8 52 60
Chart - 4.
Similar to the smoking habit distribution, tobacco chewing habit
distribution is also high among the older adults within the study group
2% 5% 7%
10%
35%
42%
21-40 41-60 >61
Percentage
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Age distribution
Age distribution of Betel quid/pan
masala/gutkha chewing habits
Non-Chewers
Chewers
Table - 5. Age distribution of Oral cavity
lesions
Histopathological
Diagnosis
Age distribution
Total21-
40
41-
60 >61
Benign 3 3 6
Infl. lesion 2 2 4
Negative 1 1 1 3
Pre malignant 4 4
SCC Moderately diff 2 15 14 31
SCC Poorly diff 1 1
SCC Well diff 2 3 6 11
Grand Total 7 24 29 60
Chart - 5.
Squamous cell carcinoma is more prevalant among patients in the age group of 40
years and above.
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Table - 6. Sex distribution of smoking habit
Smoking habits Females Males Total
Non-Smokers 22 3 25
Smokers 35 35
Total 22 38 60
Chart - 6.
Smoking habit is absent among the females of this study group.
37%
0%5%
58%
Non-Smokers Smokers
Percentage
of cases
Habits
Sex distribution of Tobacco smoking
Females
Males
Table - 7. Sex distribution of tobacco chewing habit
Tobacco chewing habit Females Males Total
Non-chewer 5 3 8
Chewer 17 35 52
Total 22 38 60
Chart - 7.
Tobacco chewing habit is seen among the females and it is around 28%. Among
the both smoking and tobacco chewing distribution only 5% of males have no
history of bad habits.
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5.00%
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Percentage
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Sex distribution of Betel quid/pan
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Females
Males
Table –8. Sex distribution of p53 staining.
Intensity of p53 staining Females Males Total
- 7 5 12
+ 2 3 5
++ 7 13 20
+++ 6 17 23
Total 22 38 60
Chart–8.
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Table - 9. Sex distribution of Oral Cavity lesions
Histopathological
diagnosis
No. of Cases TotalFemales Males
Non-Malignant lesions 6 7 13
Malignant lesions 16 31 47
Total 22 38 60
Chart - 9.
Non-malignant lesions show almost equal distribution among both sex whereas
among malignant lesions there is increased prevalance among males.
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66%
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Table - 10. Site distribution of Oral cavity lesions
SITE OF LESION NO. OF CASES
Buccal mucosa 20
Tongue 18
Alveolus 8
Hard palate 6
Floor of mouth 3
Lip 2
Soft palate 2
Tonsil 1
Total 60
Chart - 10.
Buccal mucosa and tongue are the common sites involved in study group.
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Table - 11. Distribution of Oral Cavity lesions among smokers and non-smokers.
Histopathological Diagnosis
Non-
Smokers Smokers Total
SCC Well differentiated 3 8 11
SCC Moderately differentiated 11 20 31
SCC Poorly differentiated 1 1
Pre malignant 2 2 4
Benign 2 4 6
Inflammatory lesion 4 4
Negative 3 3
Total 25 35 60
Chart – 11.
Percentage distribution of cases within each diagnosed cases shows that there is increased
percentage of cases among smokers indicating that there is positive correlation between
smoking and malignancy.
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Table - 12. Distribution of Oral Cavity lesions among Tobacco Chewers and Non-
chewers
Histopathological Diagnosis Non-chewers Chewers Total
SCC Well differentiated 11 11
SCC Moderately differentiated 1 30 31
SCC Poorly differentiated 1 1
Pre malignant 1 3 4
Benign 2 4 6
Inflammatory lesion 2 2 4
Negative 2 1 3
Total 8 52 60
Chart- 12.
The data analysis between oral cavity lesions and the habit of tobacco chewing (Betel
quid/Pan masala/Gutkha) shows positive correlation with malignant lesions and non-
malignant lesions.
0% 3% 0% 25% 33%
50%
67%
100% 97% 100%
75% 67%
50%
33%
SCC Well
diff
SCC
Moderately
diff
SCC Poorly
diff
Pre
malignant
Benign Infl. lesion Negative
Percentage
of Cases
Histopathological Diagnosis
Distribution of Oral Cavity lesion among
Tobacco Chewers and Non-chewers
Non-chewers
Chewers
Table - 13. p53 Staining intensity among smokers and non-smokers
p53 Staining intensity Non-Smokers Smokers Total
- 10 4 14
+ 2 4 6
++ 7 12 19
+++ 6 15 21
Total 25 35 60
Chart - 13.
Data analysis of intensity of p53 staining among smokers and non-smokers
shows positive correlation. Among non-smokers most cases show negative
or weak positivity and among the smokers it shows strong positivity.
10
2
7 64 4
12
15
- + ++ +++
No. of
Cases
Intensity of p53 staining
p53 Staining intensity among smokers and
non smokers
Non-Smokers
Smokers
Table - 14. p53 staining intensity among tobacco chewers and non-
chewers
p53 Staining Intensity Non-Chewers Chewers Total
- 7 7 14
+ 6 6
++ 1 18 19
+++ 21 21
Total 8 52 60
Chart– 14.
p53 staining intensity is strongly positive among the tobacco chewers
and predominantly negative in patients with no history of tobacco
chewing in any form.
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Table - 15. p53 marker status in Squamous cell carcinoma and other lesions.
Histopathological Diagnosis p53 Negative p53 Positive Total
Squamous cell Carcinoma 2 41 43
Non-malignant 12 5 17
Total 14 46 60
Chart - 15.
On percentage analysis of p53 immunostaining shows that positive staining is
more among the cases reported as Squamous cell carcinoma and shows weak
positivity or negative staining in non-malignant lesions.
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Table -16. p53 staining intensity in squamous cell carcinoma
Squamous cell Carcinoma
p53 Staining intensity
TotalNegative / weakly
positive
Strongly
positive
SCC Well differentiated 2 9 11
SCC Moderately differentiated 3 28 31
SCC Poorly differentiated 1 1
Grand Total 5 38 43
Chart - 16.
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Table - 17. p53 staining intensity among Oral Cavity lesions
Histopathological diagnosis
p53 Staining intensity
Total
- + ++ +++
SCC Well differentiated 1 1 1 8 11
SCC Moderately differentiated 1 2 16 12 31
SCC Poorly differentiated 1 1
Pre malignant 1 1 2 4
Benign 4 2 6
Inflammatory lesion 4 4
Negative 3 3
Grand Total 14 6 19 21 60
Chart - 17.
On percentage analysis of p53 immunostaining shows that positive
staining is more among the cases reported as Squamous cell carcinoma
and shows weak positivity or negative staining in non-malignant lesions.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
SCC Well diff SCC
Moderately
diff
SCC Poorly
diff
Pre
malignant
Benign Infl. lesion Negative
Percentage
of Cases
Histopathological Diagnosis
p53 staining intensity among Oral Cavity lesions
- + ++ +++
In this study, over-expression of p53 oncoprotein was detected in 46/60 cases of
lesions of oral cavity. The immunostaining reactions for oncoprotein p53 within the
tumour cell populations were confined to the cell nuclei. Well differentiated tumours
showed a strong immunostaining for p53 along the periphery of the tumour nests
where the cells were actively proliferating, whereas the centre of the keratin pearls
remained negative for the staining. Among the 46 cases of positive lesions, 21 cases
showed strong staining (+++), 19 cases showed moderate staining (++), and 6 showed
a weak staining (+). Verrucous carcinoma samples showed weak-to-strong staining.
Normal epithelium in adjacent areas of the carcinomas remained negative for
immunostaining (figures 2 – 9). The present study found no significant relationship in
the expression of the oncoprotein with respect to the site of lesion. In most of the p53
positive cases, the subjects had a history of chronic chewing, both chewing and
smoking. In the case of chewers, the staining intensity showed a significant correlation
between the numbers of the betel quids chewed per day. Over-expression of the p53
oncoprotein showed a slight predilection for the male sex and most of them had
smoking habits coupled with chewing [33/38 (87%) males vs. 15/22 females, (68%)].
Statistical analysis of p53 expression and Squamous cell carcinoma
To analyse the data, the Fisher Exact test of significance for association between two
binary variables was used. It is useful replacement for the common X2 test in the case
of 2x2 tables where some of the cells have very small - frequencies.
Table –18
The Fischer exact test statistic value is 0, which is significant at p value < 0.05. The
test has a positive predictive value of 97% and negative predictive value of 84%,
indicating a highly significant association between malignancy and p53 oncoprotein
expression. The sensitivity of the test is 93% and specificity is 94%.
p53 Squamous cell carcinoma Non-malignant Total
Positive 40 1 41
Negative 3 16 19
Total 43 17 60
Statistical analysis of smoking and p53 expression
Table –19
p53
Smoking Habit - cigarettes/beedis per day
Total
Less than 5 More than 5
Negative 18 1 19
Positive 18 23 41
Grand Total 36 24 60
The Fischer exact test statistic value is 0.000151. The result is significant at p < 0.05,
indicating a highly significant association between smoking cigarettes and
development p53 positive staining in the cells. Hence a patient who smokes more than
5 cigarettes or beedis per day has a higher probability of developing p53 mutation than
a patient with no history of smoking.
Statistical analysis of Betel quid/Pan masala/Gutkha chewing and p53 expression
Table – 20
The Fischer exact test statistic value is 1E-06. The result is significant at p < 0.05,
indicating a significant association between chewing tobacco products and developing
p53 positive immunoexpression in oral lesions. Hence a patient who chews more than
5 sachets of betel quid/pan masala/gutkha is more likely to develop p53 mutation than
a patient who does not have tobacco chewing habit.
p53
Chewing Habit - sachets of Betel quid/Pan
masala/Gutkha per day Total
Less than 5 More than 5
Negative 18 1 19
Positive 11 30 41
Grand Total 29 31 60
DISCUSSION
DISCUSSION
A number of studies have shown that normal p53 acts as a molecular policeman which
monitors genetic damage, or strand breaks in the DNA (Lane and Benchimol, 1990;
Montenarh, 1992). It is postulated that p53 could have both a role in regulating
transcription of genes that suppress cell proliferation, perhaps those affecting passage
from late GI to S phase of the cell cycle (50), and a biological function as a GI
checkpoint control allowing the repair of DNA damage (48). The wild-type of the
protein has a shorter half-life when compared to mutant variety of the protein which is
more stable and is, in part, responsible for malignant transformation (67). Over-
expression of the p53 oncoprotein has been reported in oral squamous cell
carcinomas. The staining intensity of p53 also shows a linear correlation with
increasing degrees of dysplasia and the appearance of SCC (65). Since more than 70%
of the cases that have been studied here show the presence of p53 oncoprotein, it is
possible that mutation of p53 plays a role in the progression of oral malignancies from
a state of dysplasia to squamous cell carcinomas. It is also possible that there may be
mutation in - one of the alleles, and the remaining allele is lost during a later period. It
has been suggested that mutation in one of the alleles and/or loss of the remaining
allele leads to malignant transformation (21). The fact that the expression of the
protein is higher for oral SCCs demonstrating more than 40% of cells with binding to
proliferating cell nuclear antigen (PCNA) shows that malignancy might be promoted
due to an increase in the cell cycle somehow related to p53 oncoprotein expression
(76).In a study by Soussi et al. (1994) have suggested that more than 90% of missense
mutations account for the immunohistochemically detectable p53 whereas nonsense
mutations, which arise from alterations in nucleotide sequences that convert triplet
codons for given amino acids into termination codons, and/or deletions which are not
immunohistochemically detectable. The loss of function of the wild-type allele and/or
the presence of missense mutations may, in part, explain the increased positive p53
staining in oral carcinomas. To analyse this present study used immunohistochemical
technique to retrieve the antigen. Further experimental evidence is needed to support
this view. As the staining reaction of the protein is limited to the nucleus, it appears
that the mutant protein that have acquired a dominant transforming activity remain in
the nucleus (77). The process of carcinogenesis is presumed to be taking place in a
step-wise manner and multiple genetic changes are required before a normal cell turns
fully neoplastic (78). Etiological factors such as tobacco and alcohol have been shown
to induce a variety of genetic changes in human neoplasia including head and neck,
and oral squamous cell carcinomas (79). Tobacco has also been implicated in the
causation of lung cancer (80) and bladder cancer (81).
Several investigators have suggested that unrepaired DNA damages might lead to
mutation in the p53 gene by inducing G+T transversions (82). The carcinogens like
Tobacco specific nitrosamines (TSNA) and areca nut specific nitrosamines (ASNA)
are able to induce mutations in exons 5-9 of p53 gene and the most commonly
observed changes are the GA transitions (83) and GT transversions (84). It has
also been suggested that in vitro immortalization is a rate-limiting step in
carcinogenesis. Recent studies have shown that p53 is needed for immortalization and
that the gene may get inactivated by factors such as HPV types 16 and 18 (85) or it
may have some role in programmed cell death or apoptosis (63). The wild-type p53
gene product can reduce the transforming efficiency of many oncogenes and can
suppress tumour growth, whereas mutant forms can lead to malignant transformation,
especially when the protein is co-expressed with cellular oncogenes such as ras (86).
The results of this study although differ from that of Ranasinghe and his associates
(1993) stating that p53 expression is low in oral squamous cell carcinoma, strongly
suggests that p53 oncoprotein is involved in the tumourigenesis of oral SCCs. Recent
studies have shown that p53 may play an important role in the causation of oral
cancers in habitual tobacco betel quid chewers, and that the expression of p53
oncoprotein shows a relationship with the number of quids per day and the frequency
of chewing (87). Studies have also shown that ras oncogene and p53 gene form the
part of the machinery which controls cellular proliferation and or differentiation. In
normal cells, cyclin-dependent kinases (CDK) exist in multiple active forms
containing cyclins, proliferating nuclear antigen (PCNA), and p21 (88). As such, p21
is considered to be an inhibitor of cellular proliferation(94). Studies by Xiong, Zhang
and Beach (1993) have shown that there is loss of p21 protein from CDK complexes
in cells obtained from patients with Li-Fraumeni Syndrome (LFS), a syndrome that
represents an inherited familial disorder with a relatively high susceptibility for early
onset of various tumours (89). It is known that LFS patients already have a copy of
p53 mutant allele while the remaining wild-type p53 allele might undergo mutation
(90) and that their cells carry no known DNA viruses (91). Therefore, the loss of p53
gene may alter normal functioning of the cell cycle and the functions of other cell
cycle-associated proteins which act to cooperate during malignant transformation (49).
It is possible that the normal tumour suppressor function of p53 is mediated through
p21 or p21 is dependent upon the p53 pathway to effect the changes in cell
proliferation and CDK complexes (92). Although the incidence of ras mutations is
comparatively low in oral squamous cell carcinomas in Western countries (93), H-ras
analysis in the Indian oral cancer patient group (Bombay) has revealed a high
percentage of tumour-associated loss of heterozygosity (LOH) in about 35% of the
cases (72). A still higher percent of ras mutation (50-70%) has been documented in
oral SCC from South India and this study has also shown that the ras oncogene is, in
part, responsible for malignant transformation (94). Hence, it is possible that there
may be co-expression of p53 with the mutation of H-ras and that these mutated
proteins are essential for malignant transformation or may have a synergistic effect on
malignant transformation at least in some oral cancers caused by tobacco betel quid
chewing. Also, the ingredients of the betel quid may play a decisive role in the
causation of p53 mutations. As the betel quid in Tamilnadu does not contain any
additional spices (95) as opposed to Northern India, it may be possible that this patient
group lack the protective effects, if at all they have any, from these added condiments.
The phenolic compounds in areca nut may trap nitrites and may exhibit a strong
anticlastogenic and antimutagenic effect (96), but these compounds may show
chromosome damaging effects when used in combination with other ingredients of the
betel quid such as tobacco, catechu, betel leaf, lime, and spices and flavouring agents
(97). Studies have shown that the exposure time to the carcinogens in tobacco and the
age at the very first exposure is quite significant in the causation of oral cancers (97).
Such factors like the duration of exposure to tobacco, the amount of tobacco, the age
at the very first exposure are also important as the areca nut-related phenolics stay in
the saliva of the habitual chewers only for a limited time (98); it usually disappears
soon after expectoration of the macerated betel quid mixture (99). There is
epidemiological evidence that the tobacco and betel quid chewers of Tamilnadu
usually keep the chewing mixture for prolonged periods in their mouth and most of
them start the chewing habits at an early age (95). This may increase the exposure
time to the carcinogens when compared to subjects from other places such as - Sri
Lanka (10-30 min.), (100). Unlike other places, in Tamilnadu, the habitual chewers
prefer slaked lime to stone lime (101) which obviously will increase the pH along with
tobacco thereby inflicting more damage onto the tissues (102). Reactive oxygen
species generated from the chewing mixture is known to cause genetic damage in a
sequential dose-dependent manner (103) and cell death (104). But there is no
conclusive evidence to show that the presence of excess lime and the lime-induced
tissue injury would affect the p53 expression.
It appears that some carcinogens in (105) tobacco act only at certain sites of the gene
(69) and that moderate to heavy smokers, unlike non-smokers, are likely to have
multiple mutations (44). It is also likely that there exists a synergistic effect between
the various etiologic factors and the incidence of genetic damage (106). It has been
shown that nutritional deficiencies and tobacco chewing and smoking habits are more
prevalent in the rural population of India, which constitutes more than 80% of the total
population (107). Chilli, a main ingredient of the diet in the southern parts of India, is
known to contain mutagenic and tumour promoting agents (108) have shown that
there is an 11-13 fold increase in the incidence of oral cancer in habitual chewers who
do not prefer a vegetarian diet. There is epidemiological evidence that the relative risk
for beedi is much higher when there are other habits such as tobacco chewing and
alcohol drinking (109). The fact that most of the male subjects in the present study had
chronic tobacco  betel chewing and beedi smoking habits may account for the increase
incidence of genetic damage which, in turn, predispose them to oral cancer. As
reported by many investigators, alcohol may have a synergistic effect since most
people in the rural areas in Southern India use home-brewed alcohol which contains
about 40-50% ethanol (95). In effect, the aforesaid etiologic factors may act in a
sequential manner to bring about the malignant changes.
The number of betel quids chewed per day, exposure to the carcinogens and the
presence of more than one habit is important in the process of carcinogenesis. 52/60
(87%) of the patients from the present study were chewers. Above normal levels of
natural radiation, the carcinogens in the tobacco betel quid mixture, and the beedi
smoke alone or in combination with one another may play a role in the incidence of
mutation outside the 'conserved regions' of p53. Further studies using advanced
techniques such as polymerase chain reaction (PCR) coupled with direct DNA
sequencing may help elucidate the molecular aspects of oral cancers in tobacco and
betel quid chewers.
It has been suggested that over-expression of tumour suppressor genes is likely to be
associated with dysfunction of a common regulatory pathway in the case of
proliferation and differentiation (110). Many researchers have shown that
keratinocytes transfected with HPV types 16 and 18 tend to undergo malignant
transformation on exposure to tobacco-related carcinogens alone or in combination
with tumour promoters such as N-nitroso-N-methylurea (NMU) and phorbol esters
(111). It is possible that the tumour suppressor gene p53 may be inactivated by the
papilloma virus and that E6 protein of the virus can bind to and promote degradation
(112). As the gene acts to control transcription, its inactivation may predispose the
affected tissues to malignant transformation. Cases have been reported where there is
a negative relationship between the suppressor gene inactivation and the presence of
HPV (113). Virus-induced changes along with the tobacco-related carcinogen-induced
damage may sequentially make oral keratinocytes more prone to malignant
transformation (114).
The ingredients of the betel quid also play a major role. Unlike other places, in
Tamilnadu, all the substances are used fresh and most patients have a tendency to
leave the chewing material in their mouth for longer periods, and sometimes even
during sleep (115). This may, in turn, increase the time of exposure to the carcinogens
(95). Lime is known to contain radioactive substances which may emit α-particles as
high as 0.35 pCi which is equivalent to the amount of alpha-particles emitted from
0.53 mg/Kg u (116). Thus, it could be hazardous for people who chew continuously or
who are exposed to the excess amounts of lime as it may cause damage to the tissues
and the genetic material. Yet another possibility is that the hot and spicy food items, a
habitual action in southern parts of India, may give rise to a variety of carcinogens. A
detailed dietary analysis is required to establish the exact role of diet in oral, and head
and neck cancers. Also, southern parts of India is one of the areas where there is
relatively high inbreeding which may, in part, account for the increased rate of genetic
susceptibility.
In summary, in this tertiary care hospital based on the analysis of results p53 plays a
major role in OSCCs and this p53 overexpression may be caused by the factors such
as tobacco chewing, betel quid chewing, pan masala or gutkha chewing habits. The
genotoxic effects of tobacco, alcohol and diet-related factors may have a field
cancerization effect on the mucosa of the upper aerodigestive tract and may thereby
predispose the whole epithelium to malignant transformation (117). However, the
results of work done by Kannan et al. (1993) taken together with the present study
suggests that a correlation between the overexpression of p53 protein and ras mutation
is very likely. Further analysis of these cases at the molecular level might give some
insight into functional aspects of the etiological factors in the development of oral
cancers in habitual tobacco/betel quid chewers.
CONCLUSION
CONCLUSION
The results of the study on the levels of p53 immunoexpression show that there is
overexpression of p53 oncoprotein in SCCs of oral cavity at this tertiary care centre –
Tirunelveli Medical College, Tirunelveli. The overexpression of p53 in oral cavity
squamous cell carcinoma samples from Tirunelveli is strongly associated with the
number of betel quids chewed and the number of cigarettes or beedis smoked per day.
Other factors such as diet-related factors, natural radiation, relatively high genetic
susceptibility, and/or the presence of transforming proteins of viruses may act
sequentially to make the cells more prone to malignant transformation. p53
oncoprotein is likely to be involved in the promotion and/or progression of the
squamous cell carcinomas, and the discovery of p53 mutations in human SCCs
suggests that alterations in tumour suppressor genes play an important role in some
oral cancers (118). Although the protein is implicated in cell proliferation and/or
differentiation, more investigations are needed to decipher the molecular mechanisms
involved.
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Figure – 2.Normal squamous epithelium with acanthosis.
Figure – 3. Well differentiated squamous cell carcinoma
Figure – 4. Moderately differentiated squamous cell carcinoma
Figure – 5. Poorly differentiated squamous cell carcinoma
Figure – 6.Case showing negative staining for p53 marker
Figure – 7.Case of moderately differentiated squamous cell carcinoma showing 1+
staining for p53 marker.
Figure – 8.Case of moderately differentiated squamous cell carcinoma showing 2+
staining for p53 marker.
Figure – 9. Case of well differentiated squamous cell carcinoma showing 3+ staining
for p53 marker
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